|
|
|
| home > white papers > Clinical Trial Labelling – More Than Just Labels - Faubel & Co. Nachfolger GmbH |
|
|
 WHITE PAPERS |
|
Faubel & Co. Nachfolger GmbH
|
|
Clinical Trial Labelling – More Than Just Labels
|
|
Deciding which label is best for a particular trial project is not always easy. Labels have become multifunctional tools which are able to convey variable data in different languages, indicate first opening, product originality, support ease of use or blind study drugs. They are no longer used as mere carriers of specified contents.
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
India Pharma Forecast Record Growth For 2023 Ahead of CPHI & PMEC India
Amsterdam, 16th November 2022: India is set for record growth in
2023 after pharma manufacturers report surging international partnering
at CPHI Frankfurt. Contract Manufacturing organisations (CMO) appear to
be the biggest beneficiaries of new contracts, closely followed by API
manufacturers in the country. In fact, for the first time Indian API
manufacturing has surpassed the quality scores of even Europe’s leading
API hub – Italy – in the CPHI Annual Survey.
More info >> |
|
 |
White Papers |
 |
|
eSource: Reducing Site Workload for Better, Faster, Safer Clinical Trials
Clinical Ink
Unlike traditional electronic data capture (EDC),
SureSource, Clinical Ink’s eSource platform, was designed from the
beginning to minimize clinical trial complexity for site users. A Site Impact Survey provides
scientific evidence regarding the impact of SureSource from 517 site
users. Results confirm it significantly reduces workload, lessens
queries, and improves data quality compared to paper and EDC. In this
white paper, we quantitatively evaluate survey outcomes, provide
qualitative feedback from survey respondents, and highlight the observed
benefits of SureSource for transforming clinical research.
More info >> |
|
|
|
